Novel DX Revenue and Competitors
Estimated Revenue & Valuation
- Novel DX's estimated annual revenue is currently $3.2M per year.
- Novel DX's estimated revenue per employee is $104,000
Employee Data
- Novel DX has 31 Employees.
- Novel DX grew their employee count by 15% last year.
Novel DX's People
| Name | Title | Email/Phone |
|---|
Novel DX Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 18 | 0% | N/A | N/A |
#2 | $1.8M | 20 | 33% | N/A | N/A |
#3 | $26M | 182 | -3% | N/A | N/A |
#4 | $2M | 22 | 16% | N/A | N/A |
#5 | $30.7M | 215 | 9% | N/A | N/A |
#6 | $2.5M | 28 | 8% | N/A | N/A |
#7 | $40.1M | 287 | -7% | $158M | N/A |
#8 | $26.9M | 188 | 2% | N/A | N/A |
#9 | $1.5M | 19 | 6% | N/A | N/A |
#10 | $349.4M | 1920 | 4% | N/A | N/A |
What Is Novel DX?
Lab-quality, Clinically Actionable Results in Minutes Anywhere! Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit
keywords:N/A
N/A
Total Funding
31
Number of Employees
$3.2M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Novel DX News
... immunoassay-based products but has since evolved into a producer of novel immunodiagnostic reagents for specialty testing laboratories.
NA Proactive news snapshot: Vuzix, Cloud DX, Arizona Silver Exploration, ... are waiting for transformative medicines and covers novel chemical space while...
NA Proactive news snapshot: Vuzix, Cloud DX, Arizona Silver ... waiting for transformative medicines and covers novel chemical space while...
Other Companies in Baltimore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 31 | 3% | N/A |
#2 | $4.5M | 31 | 3% | N/A |
#3 | $2.5M | 31 | -6% | N/A |
#4 | $5.2M | 31 | -6% | N/A |
#5 | N/A | 31 | -6% | N/A |